GlassScriptPhysician profile
Bridgette M Cartwright Arnett
NPI 1730189291
$4,829.44
in general payments reported to CMS, 2019-2025
30 companies · $680 in 2025
The $680 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $980 · 2020: $555 · 2021: $532 · 2022: $404 · 2023: $555 · 2024: $1,124 · 2025: $680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,358.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,748.97 | 2019-2025 | |
| Abbvie INC. | $273.63 | 2021-2025 | Ubrelvy, Qulipta |
| Genentech USA, INC. | $224.92 | 2019-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Biogen, INC. | $206.03 | 2019-2025 | Vumerity, Tysabri |
| Celgene Corporation | $177.07 | 2021-2025 | Zeposia |
| Eisai INC. | $166.46 | 2021-2025 | |
| Lilly USA, LLC | $126.22 | 2019-2024 | Emgality, Reyvow, Amyvid |
| Alexion Pharmaceuticals, INC. | $123.73 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $74.48 | 2019-2020 | |
| Tanabe Pharma America, INC. | $73.83 | 2025 | Radicava |
| Teva Pharmaceuticals USA, INC. | $73.28 | 2024-2025 | Austedo Xr, Austedo Xr |
| Jazz Pharmaceuticals INC. | $69.46 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $65.42 | 2019 | |
| Lundbeck LLC | $63.28 | 2024 | Vyepti |
| Neurelis, INC. | $46.78 | 2024 | Valtoco |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $40.08 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $36.56 | 2024-2025 | Wainua |
| Livanova USA, INC. | $28.54 | 2020 | |
| Genzyme Corporation | $25.79 | 2019-2021 | |
| Ucb, INC. | $23.69 | 2025 | Zilbrysq |
| Emd Serono, INC. | $23.34 | 2019-2021 | |
| Catalyst Pharmaceuticals, INC. | $22.69 | 2020 | |
| Xeris Pharmaceuticals, INC. | $22.30 | 2024 | Keveyis |
| Csl Behring | $18.59 | 2019 | |
| Allergan, INC. | $14.72 | 2020 | |
| Vertical Pharmaceuticals, LLC | $14.59 | 2019 | |
| Argenx US, INC. | $13.47 | 2025 | Vyvgart, Vyvgart Hytrulo |
| Acorda Therapeutics, INC | $12.26 | 2019 | |
| Amneal Pharmaceuticals LLC | $10.87 | 2019 | |
| Sumitomo Pharma America, INC. | $8.39 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridgette Cartwright Arnett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.